Rethinking Hydroquinone: A JDD Review Every Dermatologist Should See
Did you catch the latest JDD review on hydroquinone? This concise review revisits hydroquinone’s place in treating hyperpigmentation, examining its clinical use, safety profile, and the shifting regulatory landscape that is prompting many clinicians to reassess standard practice. For practicing dermatologists and dermatology healthcare professionals, the piece frames current debates without overstating conclusions and highlights the rise of non-hydroquinone therapies and combination approaches that are drawing interest in clinics and academic settings.
The authors summarize recent evidence and regulatory developments while pointing toward practical considerations for depigmenting treatment protocols. Rather than prescribing a single pathway, the review outlines areas of consensus and unresolved questions about long term safety, comparative efficacy, and how emerging alternatives might fit into stepwise management. Readers will find a clear overview useful for patient counseling and for updating office protocols in light of changing guidance.
If you manage patients with melasma or other pigmentary disorders, this article offers a timely snapshot of where the field stands and what to watch for next. It aims to inform clinical decision making by highlighting key themes without overreaching beyond the available data.
To evaluate the review’s implications for your practice and to read the detailed analysis of alternatives, safety data, and combination strategies, read the full article in the Journal of Drugs in Dermatology. Updating your approach to hyperpigmentation treatment starts with reviewing the evidence.
Blog write-up assisted by AI
